FSD Pharma Inc. | WebDisclosure

Basculer en Français

8296	Companies
114899	Keywords
55318	Articles
62453	Press releases

Home
Companies
FSD Pharma Inc.

BRIEF

published on 06/27/2024 at 13:35, 4 months 23 days ago

FSD Pharma reçoit l'approbation du comité d'éthique pour un essai clinique de phase 1 en Australie

FSD Pharma Sclérose En Plaques Essai Clinique Lucide-21-302 Approbation HREC
PRESS RELEASE

published on 06/27/2024 at 13:30, 4 months 23 days ago

FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
FSD Pharma announces HREC approval for Lucid-21-302 trial in Australia. Lucid-21-302 is a neuroprotective compound for multiple sclerosis treatment

FSD Pharma Multiple Sclerosis Lucid-21-302 Neuroprotective Compound HREC Approval
BRIEF

published on 06/13/2024 at 13:35, 5 months 7 days ago

FSD Pharma conclut un accord exclusif avec l'USC pour la technologie des compléments alimentaires

Commercialisation Compléments Alimentaires FSD Pharma Unbuzzd™ USC
BRIEF

published on 06/13/2024 at 13:35, 5 months 7 days ago

FSD Pharma Enters Exclusive Agreement with USC for Dietary Supplement Tech

Dietary Supplements FSD Pharma Commercialization Unbuzzd™ USC
PRESS RELEASE

published on 06/13/2024 at 13:30, 5 months 7 days ago

FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
FSD Pharma Inc. enters into an exclusive option agreement with the University of Southern California to evaluate dietary supplement technology for commercialization, potentially enhancing unbuzzd™ effectiveness and expanding target markets with novel products

FSD Pharma Inc. Unbuzzd™ University Of Southern California Dietary Supplement Technology Exclusive Option Agreement
BRIEF

published on 06/04/2024 at 13:35, 5 months 16 days ago

FSD Pharma Receives Institutional Review Board Approval for Unbuzzd(TM) Study

FSD Pharma Clinical Study Unbuzzd Alcohol Intoxication Institutional Review Board
BRIEF

published on 06/04/2024 at 13:35, 5 months 16 days ago

FSD Pharma reçoit l'approbation du comité d'examen institutionnel pour l'étude Unbuzzd(TM)

FSD Pharma Étude Clinique Unbuzzd Comité D'examen Institutionnel Intoxication À L'alcool
PRESS RELEASE

published on 06/04/2024 at 13:30, 5 months 16 days ago

FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
FSD Pharma obtains IRB approval in the USA for the METAL-2 trial, allowing recruitment of clinical trial participants for alcohol intoxication research

FSD Pharma Clinical Study Alcohol Intoxication METAL-2 Trial IRB Approval
BRIEF

published on 05/31/2024 at 13:35, 5 months 20 days ago

FSD Pharma remporte une sentence d'arbitrage contre l'ancien PDG Bokhari

Biopharmaceutique FSD Pharma Litige Sentences D'arbitrage Boukhari
BRIEF

published on 05/31/2024 at 13:35, 5 months 20 days ago

FSD Pharma Wins Arbitration Award Against Former CEO Bokhari

Litigation FSD Pharma Biopharmaceutical Arbitration Awards Bokhari

Accesswire

Published on 11/21/2024 at 13:00, 20 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 20 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 20 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 20 minutes ago

Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 20 minutes ago

Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 5 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 45 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 5 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 13 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 20 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 22 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 22 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 22 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 12 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 18 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE